Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium

Sara Rafael Fernandez13 enrolled

Overview

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Infertility Infertility, Female

Interventions

Plasma rich in growth factors (PRGF-Endoret)DRUG

Intrauterine administration of PRGF

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women who signed informed consent. * Women who understand the Spanish language. * Women under 42 years Exclusion Criteria: * Thrombopenia. * Congenital or acquired uterine malformations that reduce embryo implantation or term gestation. * Ovarian tumors. * Benign uterine tumors require surgical treatment * Local acute inflammatory diseases * Patients with malignant tumors requiring chemotherapy. * Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation. * Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)

Locations (1)

Hospital Clinico San Carlos

Madrid, Spain

Outcomes

Primary Outcomes

Percentage of women who achieve an endometrial thickness equal to or greater than 7 mm

Measurement of the endometrial thickness by ultrasonography.

Time frame: 3 days after administration of PRGF

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.